Optimization of purine-nitrile TbcatB inhibitors for use in vivo and evaluation of efficacy in murine models

Jeremy P. Mallari, Fangyi Zhu, Andrew Lemoff, Marcel Kaiser, Min Lu, Reto Brun, R. Kiplin Guy

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

There are currently only four clinical drugs available for treating human African trypanosomiasis (HAT), three of which were developed over 60 years ago. Despite years of effort, there has been relatively little progress towards identifying orally available chemotypes active against the parasite in vivo. Here, we report the lead optimization of a purine-nitrile scaffold that inhibits the essential TbcatB protease and its evaluation in murine models. A lead inhibitor that had potent activity against the trypanosomal protease TbcatB in vitro and cultured parasites ex vivo was optimized by rationally driven medicinal chemistry to an inhibitor that is orally available, penetrates the CNS, has a promising pharmacokinetic profile, and is non-toxic at 200 mg/kg in a repeat dosage study. Efficacy models using oral administration of this lead inhibitor showed a significantly increased survival time in Trypanosoma brucei brucei infected mice but little effect on Trypanosoma brucei rhodesiense infected mice.

Original languageEnglish (US)
Pages (from-to)8302-8309
Number of pages8
JournalBioorganic and Medicinal Chemistry
Volume18
Issue number23
DOIs
StatePublished - Dec 1 2010

Fingerprint

Nitriles
Parasites
Peptide Hydrolases
Trypanosoma brucei rhodesiense
African Trypanosomiasis
Trypanosoma brucei brucei
Pharmacokinetics
Pharmaceutical Chemistry
Scaffolds
Oral Administration
Survival
Pharmaceutical Preparations
Lead
purine

Keywords

  • Human African trypanosomiasis
  • Parasite
  • Protease inhibitor
  • TbCatB

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Optimization of purine-nitrile TbcatB inhibitors for use in vivo and evaluation of efficacy in murine models. / Mallari, Jeremy P.; Zhu, Fangyi; Lemoff, Andrew; Kaiser, Marcel; Lu, Min; Brun, Reto; Guy, R. Kiplin.

In: Bioorganic and Medicinal Chemistry, Vol. 18, No. 23, 01.12.2010, p. 8302-8309.

Research output: Contribution to journalArticle

Mallari, Jeremy P. ; Zhu, Fangyi ; Lemoff, Andrew ; Kaiser, Marcel ; Lu, Min ; Brun, Reto ; Guy, R. Kiplin. / Optimization of purine-nitrile TbcatB inhibitors for use in vivo and evaluation of efficacy in murine models. In: Bioorganic and Medicinal Chemistry. 2010 ; Vol. 18, No. 23. pp. 8302-8309.
@article{5ac79b56bd454a3f9f0a10356bdc5b78,
title = "Optimization of purine-nitrile TbcatB inhibitors for use in vivo and evaluation of efficacy in murine models",
abstract = "There are currently only four clinical drugs available for treating human African trypanosomiasis (HAT), three of which were developed over 60 years ago. Despite years of effort, there has been relatively little progress towards identifying orally available chemotypes active against the parasite in vivo. Here, we report the lead optimization of a purine-nitrile scaffold that inhibits the essential TbcatB protease and its evaluation in murine models. A lead inhibitor that had potent activity against the trypanosomal protease TbcatB in vitro and cultured parasites ex vivo was optimized by rationally driven medicinal chemistry to an inhibitor that is orally available, penetrates the CNS, has a promising pharmacokinetic profile, and is non-toxic at 200 mg/kg in a repeat dosage study. Efficacy models using oral administration of this lead inhibitor showed a significantly increased survival time in Trypanosoma brucei brucei infected mice but little effect on Trypanosoma brucei rhodesiense infected mice.",
keywords = "Human African trypanosomiasis, Parasite, Protease inhibitor, TbCatB",
author = "Mallari, {Jeremy P.} and Fangyi Zhu and Andrew Lemoff and Marcel Kaiser and Min Lu and Reto Brun and Guy, {R. Kiplin}",
year = "2010",
month = "12",
day = "1",
doi = "10.1016/j.bmc.2010.09.073",
language = "English (US)",
volume = "18",
pages = "8302--8309",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "23",

}

TY - JOUR

T1 - Optimization of purine-nitrile TbcatB inhibitors for use in vivo and evaluation of efficacy in murine models

AU - Mallari, Jeremy P.

AU - Zhu, Fangyi

AU - Lemoff, Andrew

AU - Kaiser, Marcel

AU - Lu, Min

AU - Brun, Reto

AU - Guy, R. Kiplin

PY - 2010/12/1

Y1 - 2010/12/1

N2 - There are currently only four clinical drugs available for treating human African trypanosomiasis (HAT), three of which were developed over 60 years ago. Despite years of effort, there has been relatively little progress towards identifying orally available chemotypes active against the parasite in vivo. Here, we report the lead optimization of a purine-nitrile scaffold that inhibits the essential TbcatB protease and its evaluation in murine models. A lead inhibitor that had potent activity against the trypanosomal protease TbcatB in vitro and cultured parasites ex vivo was optimized by rationally driven medicinal chemistry to an inhibitor that is orally available, penetrates the CNS, has a promising pharmacokinetic profile, and is non-toxic at 200 mg/kg in a repeat dosage study. Efficacy models using oral administration of this lead inhibitor showed a significantly increased survival time in Trypanosoma brucei brucei infected mice but little effect on Trypanosoma brucei rhodesiense infected mice.

AB - There are currently only four clinical drugs available for treating human African trypanosomiasis (HAT), three of which were developed over 60 years ago. Despite years of effort, there has been relatively little progress towards identifying orally available chemotypes active against the parasite in vivo. Here, we report the lead optimization of a purine-nitrile scaffold that inhibits the essential TbcatB protease and its evaluation in murine models. A lead inhibitor that had potent activity against the trypanosomal protease TbcatB in vitro and cultured parasites ex vivo was optimized by rationally driven medicinal chemistry to an inhibitor that is orally available, penetrates the CNS, has a promising pharmacokinetic profile, and is non-toxic at 200 mg/kg in a repeat dosage study. Efficacy models using oral administration of this lead inhibitor showed a significantly increased survival time in Trypanosoma brucei brucei infected mice but little effect on Trypanosoma brucei rhodesiense infected mice.

KW - Human African trypanosomiasis

KW - Parasite

KW - Protease inhibitor

KW - TbCatB

UR - http://www.scopus.com/inward/record.url?scp=78249281023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78249281023&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2010.09.073

DO - 10.1016/j.bmc.2010.09.073

M3 - Article

C2 - 21051236

AN - SCOPUS:78249281023

VL - 18

SP - 8302

EP - 8309

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 23

ER -